Avidity Partners Management LP Phathom Pharmaceuticals, Inc. Transaction History
Avidity Partners Management LP
- $445 Million
- Q1 2025
A detailed history of Avidity Partners Management LP transactions in Phathom Pharmaceuticals, Inc. stock. As of the latest transaction made, Avidity Partners Management LP holds 800,000 shares of PHAT stock, worth $3.46 Million. This represents 1.13% of its overall portfolio holdings.
Number of Shares
800,000
Previous 1,390,100
42.45%
Holding current value
$3.46 Million
Previous $11.3 Million
55.56%
% of portfolio
1.13%
Previous 1.28%
Shares
16 transactions
Others Institutions Holding PHAT
# of Institutions
152Shares Held
66.6MCall Options Held
94KPut Options Held
55.5K-
Frazier Life Sciences Management, L.P. Menlo Park, CA10.1MShares$43.8 Million3.99% of portfolio
-
Medicxi Ventures Management (Jersey) LTD7.46MShares$32.3 Million12.73% of portfolio
-
Jennison Associates LLC7.04MShares$30.5 Million0.03% of portfolio
-
Invesco Ltd. Atlanta, GA3.65MShares$15.8 Million0.0% of portfolio
-
Carlyle Group Inc. Washington, DC3.5MShares$15.1 Million27.15% of portfolio
About Phathom Pharmaceuticals, Inc.
- Ticker PHAT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,175,200
- Market Cap $170M
- Description
- Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also develo...